In this context, studies have demonstrated that MSCs have anti-inflammatory and immune-modulatory effects in diverse types of tissue injury and allergic inflammation. Over the past decade, MSCs isolated from various tissues including bone marrow, adipose, or cord blood, have been shown to lack immunogenicity and thus, can be used for allogeneic or autologous cellular treatment in a variety of diseases. Despite recent advances in the treatment of symptoms with new pharmaceutical drugs and molecules, there remains no effective treatment to attenuate disease progression or reverse the COPD and emphysematous changes. In addition to their regenerative properties, MSCs have recently been shown to have unique immune-modulatory and anti-inflammatory properties that render the MSCs as potential treatment options for a variety of kinds of inflammatory disorders including chronic obstructive pulmonary disease (COPD).ĬOPD is the third-leading cause of death in the United States. Mesenchymal stem cells (MSCs) are multi-potent stem cells that have fibroblast-like morphology and the capacity to differentiate into chondrocytes, osteoblasts, adipocytes and muscle cells under different micro-environmental conditions, culture media, and supplements. Over the last two decades, tremendous progress has been made in the field of regenerative medicine and stem cell biology. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Ĭompeting interests: The authors have declared that no competing interests exist. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: All relevant data are within the paper and its Supporting Information files.įunding: This work was supported by WonKwang University Fund in the year 2013. Received: DecemAccepted: Published: June 9, 2016Ĭopyright: © 2016 Liu et al. PLoS ONE 11(6):Įditor: M Consuelo del Cañizo, University Hospital of Salamanca, SPAIN The mechanism of MSC therapy in COPD is through ameliorating airway inflammation (Hedges’s g = -2.956 ± 0.371 with 95% CI: -3.683 ~ -2.229, P< 0.001) and stimulating cytokine synthesis that involves lung tissue repair (Hedges’s g = 3.103 ± 0.734 with 95% CI: 1.664 ~ 4.541, P< 0.001).Ĭitation: Liu X, Fang Q, Kim H (2016) Preclinical Studies of Mesenchymal Stem Cell (MSC) Administration in Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review and Meta-Analysis. A total of 20 eligible studies were included in the current systematic review.
Random effect model was used due to the heterogeneity between the studies. The pooled Hedges’s g with 95% confidence intervals (95% CIs) was adopted to assess the effect size.
#Stem cell treatment for copd software
Statistical analysis was performed using the Comprehensive Meta-Analysis software (Version 3).
A systematic search of electronic databases was performed.
0 kommentar(er)
